Mendel Capital Management’s Johnson & Johnson JNJ Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$2.11M Sell
8,308
-19
-0.2% -$4.43K 0.95% 21
2026
Q1
$2.04M Buy
+8,327
New +$1.94M 1.02% 20
2025
Q3
$1.53M Buy
8,230
+179
+2% +$30.7K 0.8% 30
2025
Q2
$1.23M Buy
8,051
+134
+2% +$20.6K 0.7% 38
2025
Q1
$1.31M Buy
7,917
+121
+2% +$18.9K 0.79% 33
2024
Q4
$1.13M Sell
7,796
-1,063
-12% -$165K 0.68% 38
2024
Q3
$1.44M Sell
8,859
-203
-2% -$32.3K 0.88% 27
2024
Q2
$1.32M Buy
9,062
+31
+0.3% +$4.61K 0.86% 25
2024
Q1
$1.43M Buy
9,031
+349
+4% +$55.6K 0.95% 22
2023
Q4
$1.36M Buy
8,682
+234
+3% +$35.9K 0.98% 23
2023
Q3
$1.32M Buy
8,448
+13
+0.2% +$2.15K 1.08% 22
2023
Q2
$1.4M Sell
8,435
-21
-0.2% -$3.39K 1.12% 15
2023
Q1
$1.31M Buy
8,456
+356
+4% +$57.5K 1.18% 14
2022
Q4
$1.43M Sell
8,100
-24
-0.3% -$4.14K 1.49% 12
2022
Q3
$1.33M Buy
8,124
+234
+3% +$39.6K 1.56% 12
2022
Q2
$1.4M Sell
7,890
-83
-1% -$14.8K 1.57% 12
2022
Q1
$1.41M Buy
7,973
+296
+4% +$50.4K 1.34% 12
2021
Q4
$1.31M Buy
+7,677
New +$1.26M 1.21% 14

Other funds holding JNJ

Mendel Capital Management's JNJ Position: Q2 2026 in Review

Mendel Capital Management reduced its Johnson & Johnson (JNJ) stake by 0.23% in Q2 2026, selling an estimated $4.43K and leaving 8,308 shares worth $2.11M. The position accounts for 0.95% of the portfolio, ranked #21.

Mendel Capital Management first reported a position in JNJ in Q4 2021 and has held it in 18 quarters since. 2,379 funds tracked by Wall St. Rank hold JNJ as of Q2 2026.

  • Mendel Capital Management held 8,308 shares of Johnson & Johnson worth $2.11M as of Q2 2026.
  • Mendel Capital Management sold 19 Johnson & Johnson shares in Q2 2026, an estimated $4.43K.
  • Johnson & Johnson made up 0.95% of Mendel Capital Management's portfolio in Q2 2026, its #21 holding.
  • Mendel Capital Management first reported a position in Johnson & Johnson in Q4 2021 and has held it in 18 quarters since.
  • 2,379 funds tracked by Wall St. Rank held Johnson & Johnson as of Q2 2026.

Based on Mendel Capital Management's 13F filing for Q2 2026, filed 21 Jul 2026.